MedSci参加第四届国际生物医药产业发展创新论坛

2011-04-22 MedSci原创 MedSci原创

    由中欧生物医药委员会(SEBMC)发起主办的第四届国际生物医药产业发展创新论坛暨国际创新药物研发与转化医学峰会于2011年4月21日正式开幕。来自美国、欧洲、中国及亚太地区的生物制药、新药研发、创新药物研发外包、医药临床研究、转化医学领域400多名代表和全球顶尖药物及医学专家参加本次会议。     MedSci代表也有幸参加了

    由中欧生物医药委员会(SEBMC)发起主办的第四届国际生物医药产业发展创新论坛暨国际创新药物研发与转化医学峰会于2011年4月21日正式开幕。来自美国、欧洲、中国及亚太地区的生物制药、新药研发、创新药物研发外包、医药临床研究、转化医学领域400多名代表和全球顶尖药物及医学专家参加本次会议。

    MedSci代表也有幸参加了本次盛会,会中不少企业人士也表示,需要一家综合实力强盛的学术服务机构来处理内部的学术问题,MedSci正好是他们所需。

 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690227, encodeId=b6c4169022e5b, content=<a href='/topic/show?id=805b244019d' target=_blank style='color:#2F92EE;'>#产业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24401, encryptionId=805b244019d, topicName=产业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=208e29003854, createdName=12498fa0m20暂无昵称, createdTime=Tue Oct 18 18:19:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285122, encodeId=2b6512851221a, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408580, encodeId=1ecc140858069, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605585, encodeId=7d58160558528, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620477, encodeId=566e16204e74d, content=<a href='/topic/show?id=a2f26926177' target=_blank style='color:#2F92EE;'>#生物医药产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69261, encryptionId=a2f26926177, topicName=生物医药产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=062820130374, createdName=bluefate128, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690227, encodeId=b6c4169022e5b, content=<a href='/topic/show?id=805b244019d' target=_blank style='color:#2F92EE;'>#产业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24401, encryptionId=805b244019d, topicName=产业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=208e29003854, createdName=12498fa0m20暂无昵称, createdTime=Tue Oct 18 18:19:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285122, encodeId=2b6512851221a, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408580, encodeId=1ecc140858069, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605585, encodeId=7d58160558528, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620477, encodeId=566e16204e74d, content=<a href='/topic/show?id=a2f26926177' target=_blank style='color:#2F92EE;'>#生物医药产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69261, encryptionId=a2f26926177, topicName=生物医药产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=062820130374, createdName=bluefate128, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690227, encodeId=b6c4169022e5b, content=<a href='/topic/show?id=805b244019d' target=_blank style='color:#2F92EE;'>#产业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24401, encryptionId=805b244019d, topicName=产业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=208e29003854, createdName=12498fa0m20暂无昵称, createdTime=Tue Oct 18 18:19:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285122, encodeId=2b6512851221a, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408580, encodeId=1ecc140858069, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605585, encodeId=7d58160558528, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620477, encodeId=566e16204e74d, content=<a href='/topic/show?id=a2f26926177' target=_blank style='color:#2F92EE;'>#生物医药产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69261, encryptionId=a2f26926177, topicName=生物医药产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=062820130374, createdName=bluefate128, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=)]
    2011-04-24 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690227, encodeId=b6c4169022e5b, content=<a href='/topic/show?id=805b244019d' target=_blank style='color:#2F92EE;'>#产业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24401, encryptionId=805b244019d, topicName=产业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=208e29003854, createdName=12498fa0m20暂无昵称, createdTime=Tue Oct 18 18:19:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285122, encodeId=2b6512851221a, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408580, encodeId=1ecc140858069, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605585, encodeId=7d58160558528, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620477, encodeId=566e16204e74d, content=<a href='/topic/show?id=a2f26926177' target=_blank style='color:#2F92EE;'>#生物医药产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69261, encryptionId=a2f26926177, topicName=生物医药产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=062820130374, createdName=bluefate128, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690227, encodeId=b6c4169022e5b, content=<a href='/topic/show?id=805b244019d' target=_blank style='color:#2F92EE;'>#产业发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24401, encryptionId=805b244019d, topicName=产业发展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=208e29003854, createdName=12498fa0m20暂无昵称, createdTime=Tue Oct 18 18:19:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285122, encodeId=2b6512851221a, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408580, encodeId=1ecc140858069, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605585, encodeId=7d58160558528, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620477, encodeId=566e16204e74d, content=<a href='/topic/show?id=a2f26926177' target=_blank style='color:#2F92EE;'>#生物医药产业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69261, encryptionId=a2f26926177, topicName=生物医药产业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=062820130374, createdName=bluefate128, createdTime=Sun Apr 24 04:19:00 CST 2011, time=2011-04-24, status=1, ipAttribution=)]

相关资讯

肿瘤研究和临床SCI论文设计与发表讲座通知(2010.10.12上海)

肿瘤研究和临床SCI论文设计与发表通知

MedSci祝全年会员兔年大吉之贺卡

MedSci祝全年会员兔年大吉之贺卡

MedSci “临床科研中国行”全国巡回讲座(四川、重庆站,2010.9.7-16)

MedSci “临床科研中国行”全国巡回讲座——(四川、重庆站,2010.9.7-16)

MedSci “临床科研中国行” 全国巡回讲座(重庆站,2010.9.15-16)

MedSci “临床科研中国行”全国巡回讲座——(四川、重庆站,2010.9.7-16)

MedSci “临床科研中国行”全国巡回讲座(济南站 2010.11.20)

MedSci “临床科研中国行”全国巡回讲座——济南站